

Tetrahedron Letters

Tetrahedron Letters 46 (2005) 8103-8104

A concise synthesis of denbinobin

Yu-Chieh Wang,^a Chien-Huang Lin,^b Chi-Ming Chen^{a,*} and Jing-Ping Liou^{a,*}

^aDepartment of Medicinal Chemistry, School of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC

^bGraduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan, ROC

Received 27 August 2005; revised 19 September 2005; accepted 21 September 2005 Available online 6 October 2005

Abstract—A concise synthesis of denbinobin is described via an intramolecular free radical cyclization and Fremy's salt mediated oxidation as a key reactions. A seven-step process starting from commercially available 3,5-dimethoxybenzyl bromide (6) and 2-bromoisovanillin (5) effectively constructs the natural product denbinobin (1).

© 2005 Elsevier Ltd. All rights reserved.

Denbinobin is a natural product isolated from *Dendro-bium nobile*, which structurally has a unique phenanthrene quinone skeleton.¹ It displays antitumor² and antiinflammatory³ activities. Its simple structure and novel bioactivity have attracted interest of chemists. In 2001, Krohn et al. reported the synthesis of denbinobin using a Diels–Alder reaction to make the phenanthrene quinone core.⁴ In 2002, Kraus and Zhang reported the synthesis of denbinobin with a P₄t-Bu mediated olefin cyclization as key reaction.⁵ Herein, we report a concise synthesis of denbinobin (1) starting from commercially available 2-bromoisovanillin (5) and 3,5-dimethoxybenzyl bromide (6). The intramolecular free radical cyclization and Fremy's salt mediated oxidation were the key steps in the synthesis.

Retrosynthetic analysis (Fig. 1) suggested that the phenanthrene quinone moiety of denbinobin (1) can come from the free hydroxyl group induced *para*-oxidation of substituted phenanthrene 3. The phenanthrene core structure was envisioned to come from the intramolecular free radical cyclization of bromo substituted *cis*-stilbene 4, potentially attainable via Wittig reaction of corresponding benzaldehyde and ylide precursor. The phenanthrene moiety can also be made by photocyclization from stilbenes without incorporation of bromine atom.⁴

The synthesis of natural product, denbinobin (1), is shown in Scheme 1. The key intermediate 4 was prepared by a Wittig reaction utilizing the silyl-protected

Figure 1. Retrosynthesis of denbinobin (1).

Keywords: Natural product; Free radical cyclization; Fremy's salt oxidation.

^{*} Corresponding authors. Tel.: +886 227361661x6130; fax: +886 227369558; e-mail: jpl@tmu.edu.tw

Scheme 1. Reagents and conditions: (a) PPh₃, toluene; (b) (*i*-Pr)₂NEt, TBDMSCl, THF; (c) *n*-BuLi, THF, -78 °C; (d) AIBN, Bu₃SnH, benzene; (e) TBAF, THF; (f) Fremy's salt, NaOAc, DMF, MeOH; (g) TMSI, CH₂Cl₂, rt.

2-bromisovanillin (8) and (3,5-dimethoxy-benzyl)-triphenyl-phosphonium bromide (7) as reactants.

The reaction conditions for Wittig reaction with *n*-BuLi as base in THF at -78 °C gave the trans isomer 9 and cis isomer 4 by chromatography in a ratio of 3:5 in 84% yield. The cis-olefin 4 was subjected to AIBN/ Bu₃SnH-bearing free radical cyclization⁶ to afford the desired phenanthrene 10 in 74% yield. The silyl-protected 10 was treated with tetra-n-butylammonium fluoride (TBAF) to give phenol 3⁷ in quantitative yield which is critical, as the phenolic group can be used to facilitate the oxidation forming the related quinone functionality. We tried PIFA, CAN, and Fremy's saltmediated oxidation to make the quinone functional group. Fremy's salt⁸ could convert the desired quinone 2⁹ in a yield of 82%, which was converted to denbinobin (1, 97 mg) under the conditions reported by Krohn et al.⁴ by selective demethylation in 64% yield.

In summary, the total synthesis of denbinobin (1) has been accomplished in seven steps from commercially available 2-bromisovanillin and 3,5-dimethoxybenzyl bromide. This facile methodology will be applied to synthesize denbinobin derivatives to extensively evaluate the structure–activity relationships of this class of compounds.

Acknowledgements

This research was supported by the Taipei Medical University under Grant No. TMU 93-AE1-B-03.

References and notes

- (a) Tezuka, Y.; Yoshida, Y.; Kikuchi, T.; Xu, G. J. *Chem. Pharm. Bull.* **1993**, *41*, 1346–1349; (b) See, Ref. 3; (c) Talapatra, B.; Mukhopadhyay, P.; Chaudhury, P.; Talapatra, S. K. *Indian J. Chem.* **1982**, *21B*, 386–387.
- Lee, Y. H.; Park, J. D.; Baek, N. I.; Kim, S. I.; Ahn, B. Z. Planta Med. 1995, 61, 178–180.
- Lin, T. H.; Chang, S. J.; Chen, C. C.; Wang, J. P.; Tsao, L. T. J. Nat. Prod. 2001, 64, 1084–1086.
- 4. Krohn, K.; Loock, U.; Paavilainen, K.; Hausen, B.; Schmalle, H. W.; Kiesele, H. *ARKIVOC* **2001**, *1*, 88–130.
- Kraus, G. A.; Zhang, N. Tetrahedron Lett. 2002, 43, 9597– 9599
- (a) Harrowven, D. C.; Nunn, M. I. T.; Fenwick, D. R. Tetrahedron Lett. 2002, 43, 3185–3187; (b) Hoarau, C.; Couture, A.; Deniau, E.; Grandclaudon, P. Eur. J. Org. Chem. 2001, 2559–2567.
- 7. Compound 3: mp 121–123 °C. ¹H NMR (500 MHz, CDCl₃): δ 3.95 (s, 3H), 4.03 (s, 3H), 4.08 (s, 3H), 6.84 (d, 1H, J = 2.4 Hz), 6.97 (d, 1H, J = 2.4 Hz), 7.29 (d, 1H, J = 8.5 Hz), 7.35 (d, 1H, J = 8.7 Hz), 7.39 (d, 1H, J = 8.5 Hz), 7.55 (d, 1H, J = 8.7 Hz), 9.80 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 55.5, 56.6, 57.0, 101.1, 104.0, 111.9, 114.0, 118.4, 119.2, 124.1, 127.8, 129.1, 136.4, 143.2, 148.1, 155.3, 158.3.
- 8. Kongkathip, N.; Luangkamin, S.; Kongkathip, B.; Sangma, C. C.; Grigg, R.; Kongsaeree, P.; Prabpai, S.; Pradidphol, N.; Piyaviriyagul, S.; Siripong, P. *J. Med. Chem.* **2004**, *47*, 4427–4438.
- 9. Compound **2**: mp 179–180 °C. ¹H NMR (500 MHz, CDCl₃): δ 3.93 (s, 3H), 3.93 (s, 3H,), 3.94 (s, 3H), 6.00 (s, 1H), 6.70 (d, 1H, J = 2.1 Hz), 6.77 (d, 1H, J = 2.1 Hz), 7.88 (d, 1H, J = 8.4 Hz), 8.05 (d, 2H, J = 8.4 Hz). ¹³C NMR (75 MHz, CDCl₃): δ 55.5, 55.9, 56.5, 99.1, 101.9, 106.2, 116.9, 122.6, 130.7, 132.3, 132.8, 139.0, 158.1, 160.8, 162.9, 181.0, 184.3. HRMS: found 298.0835, calcd 298.0842.